Importantly, one study assessed the effects of dabrafenib on a gefitinib-resistant NSCLC cell line (through an EGFR mutation) and found a reduction of around 30–45% in cell growth [70]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.